<DOC>
	<DOCNO>NCT00816504</DOCNO>
	<brief_summary>This study proof-of-concept clinical study design test hypothesis oral administration galactose low level circulate factor increase glomerular permeability albumin patient resistant FSGS .</brief_summary>
	<brief_title>Effect Galactose Permeblity Factor Patients With FSGS CKD Stage 5</brief_title>
	<detailed_description>Patients resistant FSGS persistent proteinuria high risk progression end stage kidney disease ( ESKD ) . A circulate factor increase glomerular permeability albumin ( Palb ) detect 50 % patient . While molecular identity factor fully establish , vitro study limit clinical experience suggest galactose reduce level FSGS permeability factor . This study pilot study determine oral administration galactose low circulate level FSGS permeability factor . Five patient biopsy proven primary FSGS - native transplant kidney , receive plasmapheresis - resistant steroid one immunosuppressive agent study . The eligibility factor presence FSGS permeability factor . The experimental intervention administration galactose , orally , 0.2 g/kg body weight/dose twice daily . duration treatment 28 day , . Patients see day 0 , 14 , 28 treatment . They see week 8 , 16 24 discontinuation galactose . Physical examination routine laboratory test ( SMAC , CBC , urine protein : creatinine ratio early morning sample ) do visit . The FSGS permeability factor assay day 0 28 treatment 6 month discontinuation galactose . The permeability factor test laboratory Virginia Savin MD ( Medical college Wisconsin ) use previously describe method . All treatment unchanged 28 day oral galactose Treatment Period . The study analyze base number patient FSGS permeability factor lower normal level .</detailed_description>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<criteria>Primary FSGS CKD Stage 5 Resistance steroid another immunosuppressive medication Secondary FSGS</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>FSGS</keyword>
	<keyword>Permeability factor</keyword>
	<keyword>Galactose</keyword>
	<keyword>Primary FSGS , resistant immunosuppressive medication</keyword>
</DOC>